

AppIn No.: 09/944,326  
Amendment Dated: August 21, 2006  
Reply to Office Action of August 7, 2006

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (previously presented) A pharmaceutical composition, comprising an antisense oligonucleotide which inhibits expression of TRPM-2 by tumor cells, and a pharmaceutically acceptable carrier suitable for human administration for providing the oligonucleotide to a mammalian subject to reduce expression of TRPM-2 wherein the antisense oligonucleotide comprises the sequence given by SEQ ID No. 4.
- 2 - 11. (canceled)
12. (previously presented) The composition of claim 1, further comprising a second antisense oligodeoxynucleotide which inhibits expression of an anti-apoptotic protein other than TRPM-2.
13. (original) The composition of claim 12, wherein the second antisense oligodeoxynucleotide is antisense Bcl-2 oligodeoxynucleotide.
14. (canceled)
15. (previously presented) The composition of claim 13, wherein the antisense oligonucleotide having the sequence given by SEQ ID No. 4 is modified to increase the stability of the ODN *in vivo*.
- 16-18. (canceled)
19. (original) An oligonucleotide consisting of the sequence set forth in Seq. ID No. 4.
- 20-22. (canceled)
23. (previously presented) The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable carrier is a lipid carrier.
24. (previously presented) The pharmaceutical composition according to claim 1, further comprising an additional antisense oligonucleotide that binds specifically to a sequence other than TRPM-2 mRNA.

Appln No.: 09/944,326

Amendment Dated: August 21, 2006

Reply to Office Action of August 7, 2006

25. (original) The pharmaceutical composition according to claim 24, wherein the additional antisense oligonucleotide binds specifically to a sequence selected from among Bcl-2, Bcl-1x and c-myc.
26. (original) The pharmaceutical composition according to claim 25, wherein the additional oligonucleotide consists of the sequence set forth in the Seq. ID No. 13.
- 27-29. (canceled)
30. (previously presented) The pharmaceutical composition of claim 1, where the oligonucleotide consists of the sequence given by SEQ ID No. 4.